Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Learn how AI-driven TechBio is revolutionizing biotech in our exclusive interview with Bullfrog AI CEO Vin Singh.

The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial ...

Insilico Medicine, an AI drug discovery company based in Hong Kong ... “We didn’t go IPO last year because we were waiting for the Phase 2 readout [of Rentosertib],” he said.

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Empire Discovery Institute (EDI), a leading non-profit drug discovery and development accelerator, is pleased to announce the appointment of Dr. Ronald Newbold as Chief Executive Officer (CEO).  Dr.

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the pharmaceutical industry.

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...